Kodiak Sciences Inc (KOD)

Currency in USD
31.520
-2.280(-6.75%)
Closed·
30.550-0.970(-3.08%)
·
KOD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.80034.478
52 wk Range
10.94047.842
Key Statistics
Prev. Close
31.52
Open
34.1
Day's Range
30.8-34.478
52 wk Range
10.94-47.842
Volume
1.05M
Average Vol. (3m)
701.83K
1-Year Change
103.4861%
Book Value / Share
0.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KOD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
69.600
Upside
+120.81%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Kodiak Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 69.600
(+120.81% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Hold36.00+14.21%-New CoverageSep 24, 2026
Goldman Sachs
Hold36.00+14.21%-New CoverageSep 24, 2026
H.C. Wainwright
Buy58.00+84.01%-MaintainSep 17, 2026
H.C. Wainwright
Buy58.00+84.01%-MaintainAug 17, 2026
JPMorgan
Buy66.00+109.39%56.00MaintainAug 03, 2026

Kodiak Sciences Inc SWOT Analysis


Market Dynamics
Uncover Kodiak's position in the competitive eye disease treatment market, where success hinges on innovative therapies and the ability to differentiate from established players.
Financial Landscape
Analyst projections reveal Kodiak's financial hurdles, with EPS forecasts of -$4.08 for FY2025. Price targets range from $3.00 to $4.00, reflecting market uncertainties.
Pipeline Potential
Delve into Kodiak's promising pipeline, including KSI-101, tarcocimab, and KSI-501, with key trial results expected between 2025 and 2026, potentially reshaping the company's future.
Kodiak's Crossroads
Explore Kodiak Sciences' pivotal moment as it navigates challenges in eye disease drug development, with its Kodiak 2.0 strategy at the forefront of potential breakthroughs.
Read full SWOT analysis

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-1.05 / -0.98
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KOD Income Statement

Compare KOD to Peers and Sector

Metrics to compare
KOD
Peers
Sector
Relationship
P/E Ratio
−8.2x−1.8x−0.4x
PEG Ratio
0.81−0.050.00
Price / Book
32.4x3.6x2.6x
Price / LTM Sales
-94.5x3.1x
Upside (Analyst Target)
120.8%257.1%55.6%
Fair Value Upside
Unlock−5.4%7.8%Unlock

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14.54M23.18%458.18M
Other Institutional Investors
72.64M76.82%2.29B
Public Companies & Retail Investors
0.000.00%0.00
Total
87.18M100.00%2.75B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Baker Bros. Advisors LP31.76%19,919,186627,853
Baker Brothers Life Sciences, L.P.29.27%18,358,772578,668

People Also Watch

72.980
AXTI
-6.18%
196.33
NTAP
+1.77%
193.87
CRDO
+0.68%
300.60
COHR
-3.15%
1,816.57
SNDK
-3.73%

FAQ

What Is the Kodiak Sciences (KOD) Stock Price Today?

The Kodiak Sciences stock price today is 31.520 USD.

What Stock Exchange Does Kodiak Sciences Trade On?

Kodiak Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Kodiak Sciences?

The stock symbol for Kodiak Sciences is "KOD."

What Is the Kodiak Sciences Market Cap?

As of today, Kodiak Sciences market cap is 1.980B USD.

What Is Kodiak Sciences's Earnings Per Share (TTM)?

The Kodiak Sciences EPS (TTM) is -4.176.

When Is the Next Kodiak Sciences Earnings Date?

Kodiak Sciences will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is KOD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Kodiak Sciences Stock Split?

Kodiak Sciences has split 0 times.

How Many Employees Does Kodiak Sciences Have?

Kodiak Sciences has 141 employees.

What is the current trading status of Kodiak Sciences (KOD)?

As of Sep 24, 2026, Kodiak Sciences (KOD) is trading at a price of 31.520 USD, with a previous close of 31.520 USD. The stock has fluctuated within a day range of 30.800 USD to 34.478 USD, while its 52-week range spans from 10.940 USD to 47.842 USD.

What Is Kodiak Sciences (KOD) Price Target According to Analysts?

The average 12-month price target for Kodiak Sciences is 69.600 USD, with a high estimate of 85 USD and a low estimate of 56 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +120.81% Upside potential.

What Is the KOD Premarket Price?

KOD's last pre-market stock price is 30.550 USD. The pre-market share volume is 5,310.000, and the stock has decreased by -0.970, or -3.080%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.